Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Check source scope before reading a dose
Resmetirom tablets (Rezdiffra) - selected U.S. label sections
Product / population
Adult REZDIFFRA oral tablets for the applicable labeled liver-disease indication.
Renal method
Qualitative mild/moderate/severe renal categories
Source revision
Revision not captured; retrieval date is not the revision date.
Retrieved
2026-09-05
Local review status
Local label summary; independent clinical review pending. Not a two-source validated protocol.
Documented differences and cautions on this drug
All record notes are retained here, including notes about sources not selected in this review.
REZDIFFRA: March 2024 mirror versus July 2026 official renal evidence
The older mirror leaves severe impairment unstudied. The newer official section addresses severe impairment explicitly. This is a dated evidence difference, not two interchangeable current instructions.
What to reconcile: Use the current official renal section in its full product context. Preserve each study method and do not extend a nondialysis finding to an unsupported dialysis regimen.
U.S. product labeling / DailyMed · Adult REZDIFFRA oral tablets for the applicable labeled liver-disease indication.
Renal method: Qualitative mild/moderate/severe renal categories Source date: Revision not captured; retrieval date is not the revision date. Retrieved: 2026-09-05
Local label summary; independent clinical review pending. Not a two-source validated protocol.
Renal impairment comment
The selected label recommends the same dosage in mild, moderate and severe renal impairment as in normal renal function. This does not remove the separate body-weight and drug-interaction requirements or establish a dialysis-specific regimen.
Selected renal sections only, not a complete monograph. Exact product, indication, patient population, renal method and all other contraindications/interactions remain controlling.
Second independent renal reference and clinician adjudication remain pending; no all-indication, dialysis or pediatric dose may be inferred from an omitted field.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.